EGFRvIII as a promising target for antibody-based brain tumor therapy.

被引:48
|
作者
Kuan C.T. [1 ]
Wikstrand C.J. [1 ]
Bigner D.D. [1 ]
机构
[1] Department of Pathology, Duke University Medical Center, Durham, 27710, NC
关键词
EGFRvIII; Glioma; Immunotherapy;
D O I
10.1007/BF02482738
中图分类号
学科分类号
摘要
Cell surface receptors are attractive candidates for targeted therapy of cancer. Growth factors and their receptors play important roles in the regulation of cell division, development, and differentiation. Among those, the epidermal growth factor receptor (EGFR) was the first identified to be amplified and/or rearranged in malignant gliomas. The most common rearranged form, EGFR type III variant (EGFRvIII), has a deletion in its extracellular domain that results in the formation of a new, tumor-specific target found in glioblastoma multiforme, as well as in breast, ovarian, prostate, and lung carcinomas. Monoclonal antibodies have been developed with specific activity against this mutant receptor. These antibodies are internalized into the cell after receptor binding. Specific antibodies, either unarmed or armed with cytotoxic agents, including radioisotopes and toxins, have shown a promising role for EGFRvIII as a target for brain tumor therapy.
引用
收藏
页码:71 / 78
页数:7
相关论文
共 50 条
  • [41] ANTIBODY-BASED THROMBOCYTOPENIA AND MANINIL-THERAPY
    GUNTHER, I
    DABELS, J
    TESSENOW, W
    SCHWAHN, D
    DEUTSCHE GESUNDHEITSWESEN-ZEITSCHRIFT FUR KLINISCHE MEDIZIN, 1977, 32 (49): : 2331 - 2333
  • [42] Antibody-based targeted therapy for gastric cancer
    Florian Lordick
    Christian Peschel
    Jörg Rüdiger Siewert
    Gastric Cancer, 2005, 8 (4) : 206 - 208
  • [43] Antibody-based therapy in Alzheimer's disease
    Pul, Refik
    Dodel, Richard
    Stangel, Martin
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (03) : 343 - 357
  • [44] Monoclonal antibody-based therapy for neuroblastoma.
    Cheung N.K.
    Current Oncology Reports, 2000, 2 (6) : 547 - 553
  • [45] Antibody-based therapies targeting the tumor antigen mesothelin
    Hassan, R.
    Pastan, I.
    ANNALS OF ONCOLOGY, 2007, 18 : 26 - 26
  • [46] Improving the tumor specificity and retention of antibody-based molecules
    Adams, GP
    IN VIVO, 1998, 12 (01): : 11 - 21
  • [47] Tumor-Associated Carbohydrate Antigen 19-9 (CA 19-9), a Promising Target for Antibody-Based Detection, Diagnosis, and Immunotherapy of Cancer
    Nakisa, Athar
    Sempere, Lorenzo F.
    Chen, Xi
    Qu, Linda T.
    Woldring, Daniel
    Crawford, Howard C.
    Huang, Xuefei
    CHEMMEDCHEM, 2024, 19 (24)
  • [48] MONOCLONAL ANTIBODY-BASED THERAPY OF A HUMAN TUMOR XENOGRAFT WITH A LUTETIUM-177-LABELED IMMUNOCONJUGATE
    SCHLOM, J
    SILER, K
    MILENIC, DE
    EGGENSPERGER, D
    COLCHER, D
    MILLER, LS
    HOUCHENS, D
    CHENG, R
    KAPLAN, D
    GOECKELER, W
    CANCER RESEARCH, 1991, 51 (11) : 2889 - 2896
  • [49] Antibody-based fusion proteins to target death receptors in cancer
    de Bruyn, Marco
    Bremer, Edwin
    Helfrich, Wijnand
    CANCER LETTERS, 2013, 332 (02) : 175 - 183
  • [50] FLT3 antibody-based therapy for leukemia
    Li, Yiwen
    DRUG DEVELOPMENT RESEARCH, 2006, 67 (06) : 495 - 500